Compare FIVN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | VIR |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2014 | 2019 |
| Metric | FIVN | VIR |
|---|---|---|
| Price | $17.93 | $9.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $26.32 | $19.63 |
| AVG Volume (30 Days) | 2.9M | ★ 4.2M |
| Earning Date | 05-21-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 17.49 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,149,088,000.00 | $68,556,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | $925.73 |
| P/E Ratio | $40.24 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $15.70 | $4.16 |
| 52 Week High | $31.75 | $10.91 |
| Indicator | FIVN | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 63.90 |
| Support Level | $18.03 | $4.95 |
| Resistance Level | $18.96 | $10.91 |
| Average True Range (ATR) | 1.15 | 0.69 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 44.63 | 69.49 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.